Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants

Area of Science:

• Neonatal Medicine
• Pediatric Audiology
• Pharmacology

Background:

• Very low birth weight (VLBW) infants are susceptible to gentamicin-induced ototoxicity.
• Sensorineural hearing loss (SNHL) is a significant concern in VLBW infants.
• The direct impact of gentamicin on SNHL in VLBW infants requires further investigation.

Purpose of the Study:

• To evaluate the association between gentamicin exposure and sensorineural hearing loss (SNHL) in very low birth weight (VLBW) infants.
• To identify risk factors and protective measures related to gentamicin use in this vulnerable population.

Main Methods:

• A case-control study involving VLBW infants (<1500g or <32 weeks gestational age) with SNHL.
• Controls were matched for gender, gestational age, birthweight, and year of birth.
• Gentamicin exposure, dosage, duration, and serum levels were analyzed.

Main Results:

• The incidence of SNHL in the VLBW population was 1.58%.
• No significant difference in gentamicin treatment proportion, cumulative dose, or duration was observed between SNHL cases and controls.
• Key pharmacokinetic parameters of gentamicin did not differ between groups.

Conclusions:

• Gentamicin exposure, within the studied parameters, did not show a statistically significant impact on SNHL in VLBW infants.
• Short-duration gentamicin therapy, therapeutic drug monitoring, and dose adjustments are crucial for minimizing potential ototoxicity.
• Further research may be warranted to explore nuanced relationships and long-term outcomes.